Interleukin-12: all 45 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by SurgeryActive, not recruitingNCT01468896Phase 1/2Results posted
• Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic MelanomaTerminatedNCT01307618Phase 2Results posted
• Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12TerminatedNCT00622401Phase 1/2Results posted
• Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.Status unknownNCT04388033Phase 1/2
• Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid TumorsActive, not recruitingNCT03030378Phase 1
• NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage ChemotherapyStatus unknownNCT02544724Phase 2
• NM-IL-12 (rHuIL-12) in Subjects With Open Surgical WoundsCompletedNCT02544061Phase 2
• A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)Active, not recruitingNCT02483312Phase 1
• Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected AdultsCompletedNCT02431767Phase 1
• Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected AdultsCompletedNCT01266616Phase 1
• Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy AdultsCompletedNCT00528489Phase 1
• Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS PatientsTerminatedNCT00057486Phase 1/2
• Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent NeuroblastomaTerminatedNCT00054405Phase 1
• Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis FungoidesTerminatedNCT00052377Phase 1/2
• Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With MelanomaCompletedNCT00031733Phase 2
• Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid TumorsCompletedNCT00028535Phase 1
• Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's LymphomaCompletedNCT00026182Phase 2
• Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00026143Phase 2
• Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00020449Phase 2
• Interleukin-12 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00019188Phase 1/2
• Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal CancerCompletedNCT00016289Phase 2
• Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00015977Phase 2
• Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug TherapyCompletedNCT00005779Phase 1
• Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid TumorsCompletedNCT00005604Phase 1
• Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast CancerCompletedNCT00004893Phase 2
• Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00004260Phase 1
• Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant MelanomaCompletedNCT00004244Phase 1
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck CancerCompletedNCT00004070Phase 1/2
• Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's LymphomaCompletedNCT00003575Phase 2
• Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced CancerCompletedNCT00003451Phase 1
• Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal CancerCompletedNCT00003439Phase 1
• Interleukin-12 in Treating Women With Metastatic Breast Cancer Who Have Received High-Dose Chemotherapy and Peripheral Stem Cell TransplantationStatus unknownNCT00003412Phase 1
• Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00003339Phase 2
• Interleukin-12 in Treating Patients With Advanced CancerCompletedNCT00003330Phase 1
• Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's DiseaseCompletedNCT00003210Phase 2
• Interleukin-12 in Treating Patients With Multiple MyelomaCompletedNCT00003149Phase 2
• Interleukin-12 in Treating Patients With Hematologic Cancers or Solid TumorsCompletedNCT00003107Phase 1
• Interleukin-12 in Treating Patients With Cancer in the AbdomenCompletedNCT00003046Phase 1
• Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the CervixCompletedNCT00003017Phase 2
• Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic MelanomaCompletedNCT00002952Phase 1/2
• Interleukin-12 in the Treatment of Severe Nontuberculous Mycobacterial InfectionsCompletedNCT00001911Phase 1
• Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex InfectionCompletedNCT00001763Phase 1
• Treatment of Chronic Cryptosporidiosis in AIDS PatientsTerminatedNCT00001128Not applicable
• A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3CompletedNCT00000857Phase 1

← Interleukin-12 overview